Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $56.33.

A number of research analysts have weighed in on AGIO shares. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Scotiabank increased their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $34.42 on Friday. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 3.03 and a beta of 0.87. The business’s fifty day moving average is $46.56 and its 200-day moving average is $45.43. Agios Pharmaceuticals has a one year low of $20.96 and a one year high of $62.58.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 1.1% in the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after acquiring an additional 63,900 shares during the period. State Street Corp increased its holdings in Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after purchasing an additional 216,484 shares during the period. Erste Asset Management GmbH purchased a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $97,199,000. Geode Capital Management LLC raised its position in Agios Pharmaceuticals by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after purchasing an additional 6,101 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Agios Pharmaceuticals by 307.8% in the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after buying an additional 855,739 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.